SEC Form 4 · accession 0001213900-26-069021
ADIAL PHARMACEUTICALS, INC. · ADIL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wendy B. Young
Director
Period of report
Jun 12, 2026
Accepted (ET)
Jun 16, 2026 · 6:14 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001513525
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-funded WarrantF2 | $0.001 | Jun 12, 2026 | P | 36,378 | A | — | — | Common Stock | 36,378 | 36,378 | D |
Explanation of responses
- F1Pursuant to the terms of that certain Pre-Funded Warrant to Purchase Common Stock, dated June 12, 2026, issued by the Issuer to the Reporting Person pursuant to a securities purchase agreement entered into by and among the Issuer, the Reporting Person and certain other parties on June 11, 2026.
- F2The pre-funded warrants to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") have no expiration date and are exercisable at any time after receiving approval of the Issuer's stockholders. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.